ReviewHeart failure clinics2016
Cardiac Syndrome X: Update.
Review in Heart failure clinics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The effect of nicorandil in patients with cardiac syndrome X: A meta-analysis of randomized controlled trials.Medicine · 2020Pooled it
- Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know.Current atherosclerosis reports · 2023Review
- Endothelial Dysfunction and Coronary Vasoreactivity - A Review of the History, Physiology, Diagnostic Techniques, and Clinical Relevance.Current cardiology reviews · 2021Review
- Increased circulating platelet and endothelial-derived microparticles in patients with cardiac syndrome X.ARYA atherosclerosis · 2021Article
- Nebivolol for improving endothelial dysfunction in cardiac syndrome-x; Is it ready for clinical use?ARYA atherosclerosis · 2019Article
- Heart rate reserve during pharmacological stress is a significant negative predictor of impaired coronary flow reserve in women.European journal of nuclear medicine and molecular imaging · 2019Article
- Increased levels of angiogenic factors in microvascular angina.Medicine and pharmacy reports · 2019Article
- Level of Anxiety and Depression in Cardiac Syndrome X.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2019Article
- Physiological Consequences of Coronary Arteriolar Dysfunction and Its Influence on Cardiovascular Disease.Physiology (Bethesda, Md.) · 2018Review
- Investigation of MTHFR gene C677T polymorphism in cardiac syndrome X patients.Journal of clinical laboratory analysis · 2018Article
- Ultrasound-Guided Percutaneous Cervical and Upper Thoracic Sympathetic Chain Neuromodulation for Upper Extremity Complex Regional Pain Syndrome.Ochsner journal · 2017Article
Corrections and comments
- Reprint of
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Cardiac Syndrome X (CSX), characterized by angina-like chest discomfort, ST segment depression during exercise, and normal epicardial coronary arteries at angiography, is highly prevalent in women. CSX is not benign, and linked to adverse cardiovascular outcomes and a poor quality of life. Coronary microvascular and endothelial dysfunction and abnormal cardiac nociception have been implicated in the pathogenesis of CSX. Treatment includes life-style modification, anti-anginal, anti-atherosclerotic, and anti-ischemic medications. Non-pharmacological options include cognitive behavioral therapy, enhanced external counterpulsation, neurostimulation, and stellate ganglionectomy. Studies have shown the efficacy of individual treatments but guidelines outlining the best course of therapy are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.